Demis Hassabis: Two Labs, Three Titles, and a $3.5B Drug Bet

Demis Hassabis now holds three formal roles inside Alphabet's AI organization: Chairman of Google DeepMind, CEO of Isomorphic Labs, and the company's first Chief Scientist. Three weeks after stepping back from day-to-day operations at DeepMind, he told Fortune he would spend more time at Isomorphic Labs, which closed a $2.1 billion Series B round in May 2026 and carries pharma partnership ceilings totalling $3 billion with Eli Lilly and Novartis.

Google DeepMind as a business

DeepMind's commercial position is easier to trace from Alphabet's financials than from its own. StartupHub.ai data shows the lab employs 8,831 people and records $1.33 billion in annual revenue, a figure that understates its contribution to Alphabet because most of DeepMind's output flows into products rather than a standalone revenue line. The clearest commercial expression of that work is the Gemini product suite, which reached 950 million monthly active users as of Alphabet's Q2 2026 earnings, with roughly 90 percent of the Fortune 100 running Gemini Enterprise, according to an Alphabet earnings blog post from July 2026.

Google Cloud, the primary commercial vehicle for AI enterprise services, grew 82 percent year over year to $24.8 billion in Q2 2026, according to Alphabet's Q2 SEC filing. That growth reflects Gemini Enterprise adoption rather than a DeepMind balance sheet line, but the causal link between the lab's model work and Alphabet's cloud business makes the cloud figure the best available proxy for DeepMind's commercial leverage. As Chairman, Hassabis retains board-level oversight of that operation while Kavukcuoglu manages the daily execution.

What Isomorphic Labs is worth

Isomorphic Labs was spun out of DeepMind in 2021 to apply AlphaFold's protein-structure technology to pharmaceutical drug discovery. Its $2.1 billion Series B round closed in May 2026, led by Thrive Capital with Alphabet, GV, MGX, Temasek, CapitalG, and the UK Sovereign AI Fund participating, according to Forbes and BioPharm International. StartupHub.ai data places the company's current valuation at $3.5 billion.

Two headline pharmaceutical deals define its commercial position. Eli Lilly signed a contract in January 2024 that included $45 million in upfront payments and potential milestones of up to $1.7 billion, according to MedPath. A parallel Novartis agreement brings the combined ceiling of both partnerships to approximately $3 billion. Hassabis told Reuters in early 2026 that Isomorphic expects to enter its first clinical trial by the end of the year, a milestone that would validate the AI-first drug design model at the stage where most pharmaceutical development fails.

In February 2026, Isomorphic released its Drug Design Engine, which the company said doubled AlphaFold 3's performance on a protein-ligand structure prediction benchmark. That benchmark measures how accurately a model predicts whether a designed molecule will bind to its intended biological target. Among AI drug discovery companies tracked by StartupHub.ai, Isomorphic sits alongside Recursion at a $3.5 billion valuation, below Chai Discovery at $3.8 billion and Insitro at $7 billion.

What the Chief Scientist title covers

The Alphabet Chief Scientist designation is a role created for Hassabis in August 2026 with no direct predecessor at the company. In practical terms it provides cross-organizational authority to advise on AGI safety, policy, and the research agenda that cuts across Google DeepMind, Google Research, and Alphabet's broader AI infrastructure. Hassabis wrote in an internal memo cited by Fortune that "AGI is close at hand and that getting the next steps right is critical for humanity," framing the designation as a strategic, not operational, mandate.

That strategic scope sits against Alphabet's largest-ever infrastructure commitment: the company's 2026 capital expenditure guidance reaches approximately $180 billion, most of it directed at AI compute, according to Tom's Hardware citing Alphabet earnings. Hassabis's cross-company science role gives him influence over how research priorities within that infrastructure are set, without requiring him to manage day-to-day procurement or deployment decisions.

What it means

The three-title structure lets Hassabis operate across entities of different maturity: DeepMind provides the research base and commercial leverage at scale, Isomorphic Labs is the direct execution vehicle for the scientific bet he has staked his next chapter on, and the Chief Scientist role provides institutional weight to coordinate between the two without being consumed by either. The practical test for 2026 is Isomorphic's first clinical trial. That milestone converts a well-funded computational hypothesis into a demonstrable clinical result, which is the step that distinguishes AI drug discovery from AI drug design.

Sources

• Fortune: Demis Hassabis steps down from Google DeepMind CEO role amid a major AI leadership shake-up
• Forbes: Isomorphic Labs' $2.1 Billion Fundraise Is The Biggest Bet Yet On AI Drug Discovery
• BioPharm International: Isomorphic Labs Raises $2.1 Billion to Expand AI-Driven Drug Discovery Platform
• MedPath: AI-Designed Drug Discovery Reaches $3 Billion Milestone as Isomorphic Labs Partners with Eli Lilly and Novartis
• SEC: Alphabet Q2 2026 Earnings (Form 8-K)
• Reuters Legal on X: Isomorphic Labs expects first clinical trial by end of 2026
• Google Blog: Alphabet Q2 2026 earnings remarks from Sundar Pichai
• Tom's Hardware: Alphabet is doubling its capital expenditure to $180 billion in 2026

Editorial standards: every claim is sourced. Tips: [email protected]